#None #Plano #Maxor #ProxsysRx #Kim Tzoumakas

Major Leadership Change at Maxor

Maxor National Pharmacy Services, a prominent player in pharmacy care solutions, recently announced the appointment of Kim Tzoumakas as its new Chief Executive Officer. Effective January 6, 2025, Ms. Tzoumakas steps into this role following the retirement of Mike Ellis, who has served as CEO since 2016 and will now transition to Chairman of the Board.

The announcement comes on the heels of Maxor's strategic partnership with ProxsysRx aimed at strengthening its position in the pharmacy management market. This combination is not only anticipated to boost Maxor's growth trajectory but also to solidify its status as the largest independent provider of pharmacy management services catering to health systems, hospitals, and clinics.

Kim Tzoumakas enters her new position with over 25 years of extensive experience in strategic and operational leadership within the healthcare landscape. Prior to joining Maxor, she served as CEO of RAYUS Radiology, well-known for its advanced diagnostic services. Tzoumakas’s expertise lies in spearheading strategic growth while nurturing organizational culture, making her a fitting choice for Maxor as it embarks on this exciting new chapter.

In her statement, Tzoumakas expressed her enthusiasm about leading Maxor, which has earned a sterling reputation in pharmacy care over the past 100 years. She articulated a commitment to leveraging the company’s unique capabilities to deliver exceptional value to clients as it transitions into this new growth phase.

The blend of services offered by ProxsysRx and Maxor is designed to create a comprehensive suite of pharmacy management solutions. This integration promises not only clinical support but also financial efficiencies for clients involved with both organizations.

As Ms. Tzoumakas mentioned, “ProxsysRx joining forces with Maxor represents a significant move to deliver integrated pharmacy care solutions to our healthcare clients. In an increasingly challenging environment, our goal is to enhance the value derived from pharmacy service lines.”

The joint services will provide clients with a vast range of pharmacy management tools, including specialty and retail pharmacy management, support for 340B optimization, as well as benefits from payer and manufacturer interactions. This comprehensive approach ensures that both Maxor and ProxsysRx clients can enhance patient access and improve outcomes while managing costs effectively.

George Salem, the current CEO of ProxsysRx, expressed his excitement about this merger, highlighting the shared commitment to innovation and patient care that both organizations foster. Following the merger, Mr. Salem will take on a supportive role as a Board Observer at Maxor, continuing to work closely with Tzoumakas and her leadership team.

Founded in 1926, Maxor has become synonymous with excellence in pharmacy services, dedicated to optimizing patient outcomes and minimizing care costs. With the addition of ProxsysRx’s capabilities, the company continues to enhance its portfolio, ensuring they remain at the forefront of the pharmacy care industry.

About the Companies

• - Maxor specializes in enhancing pharmacy services and lowering overall care costs through a tailored approach that includes custom pharmacy benefit solutions and clinical support.
• - ProxsysRx focuses on delivering effective pharmacy service strategies to health systems, providing tools to maximize prescription program benefits and streamline financial assistance for patients.

This strategic alignment between Maxor and ProxsysRx marks a pivotal point in the enhancement of pharmacy care in the healthcare sector, aiming for improved clinical outcomes and patient satisfaction.